A method for preparing platelets in vitro and culture medium thereof
By isolating CD34+ hematopoietic stem cells and using optimized culture medium and physical conditions, the problem of low platelet preparation efficiency in umbilical cord blood is solved, and platelet preparation with high purity and high yield is achieved, suitable for clinical and regenerative medicine.
Patent Information
- Application Number
- CN202210650160.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-07-16
- Filing Date
- 2022-06-09
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-06-09
AI Technical Summary
The prior art is difficult to efficiently and stably prepare large amounts of high-purity platelets from umbilical cord blood, and the platelet differentiation efficiency is low, which affects the widespread clinical application and the development of regenerative medicine.
By isolating CD34+ hematopoietic stem cells, using optimized megakaryocyte differentiation medium and platelet maturation medium, combined with magnetic separation and physical conditions (such as shaking or stirring culture), high-purity and high-yield platelet preparation is achieved in vitro.
It improves the differentiation efficiency and purity of platelets, ensures efficient methods for preparing platelets, solves the problems of insufficient cell purity and yield in the prior art, and is suitable for clinical and regenerative medical applications.
Smart Images

Figure CN115612666B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of stem cell differentiation, and more specifically to the separation, purification, proliferation and differentiation of hematopoietic stem cells from umbilical cord blood, and more specifically to a method for preparing platelets in vitro. Background Art
[0002] Platelets are part of the blood and differentiated from megakaryocytes in the bone marrow. Platelets are mainly used in the clinic to treat blood tumor diseases, and can also be used for other tumor diseases, sepsis, internal bleeding, etc. In addition, platelets are widely used in regenerative medicine, which helps wound recovery, tissue repair, and inhibit inflammation. Some ophthalmic diseases also use platelet eye drops for corneal repair or treatment of dry eyes.
[0003] Platelets are membranous structures produced by the cytoplasm shedding after the maturation of megakaryocytes. They have a short survival period in vitro. In the bone marrow, the content of megakaryocytes is extremely low (accounting for 0.01% of nuclear cells), making it difficult to obtain a large number of them and culture them in primary culture. Therefore, it is an urgent problem to increase the yield of megakaryocytes through in vitro culture and then obtain platelets efficiently.
[0004] In the prior art, the main sources of platelets are voluntary blood donation and in vitro cell culture. The former separates platelets from blood by centrifugation, pressing and other procedures. However, this technology is limited by the supply of blood, and the amount of platelets depends on the original blood source, which is relatively unstable; while the latter can prepare platelets from iPS cell technology and umbilical cord blood (Samarkanova et al., Blood Transfus. 2020, 18 (3): 208–216). Although iPS cell technology can induce cells to transform into megakaryocytes and platelets, it is still necessary to try the induction conditions, and stabilizing the cell state and efficiently obtaining megakaryocytes and platelets will be technical difficulties, time-consuming and costly. Therefore, in recent years, foreign countries have developed technology for preparing platelets from umbilical cord blood, and have attempted to apply this technology to the European GMP process (Good Manufacturing Practice) (Lawrence et al., NPJ Regen. Med. 2021, 6: 27).
[0005] At present, umbilical cord blood is mostly used in blood preparation in China to prepare plasma, such as platelet-rich plasma (PRP), and then platelets are extracted from centrifuged plasma. Therefore, the existing technology lacks a method with high production volume, high purity, and high platelet differentiation efficiency. Summary of the invention
[0006] The present invention can stably prepare a large amount of high-purity platelets from umbilical cord blood hematopoietic stem cells through megakaryocyte culture medium and platelet maturation culture medium.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] The present invention provides a method for preparing platelets in vitro, comprising the following steps:
[0009] 1) Isolate stem cells from blood samples;
[0010] 2) Cultivated in megakaryocyte differentiation medium;
[0011] 3) Replace with platelet maturation medium;
[0012] 4) Collecting mature platelets.
[0013] Preferably, the blood sample is human umbilical cord blood.
[0014] Preferably, the separation and purification method is to separate stem cells from a blood sample by magnetic force.
[0015] Preferably, the above stem cells are CD34 + Human hematopoietic stem cells.
[0016] In a preferred embodiment, the megakaryocyte differentiation medium comprises human thrombopoietin and stem cell factor.
[0017] Preferably, the megakaryocyte differentiation medium consists of SFEM medium, 50-100 ng / mL human thrombopoietin (hTPO), and 50 ng / mL stem cell factor (SCF).
[0018] More preferably, the megakaryocyte differentiation medium comprises SFEM medium, 100 ng / mL human thrombopoietin, and 50 ng / mL stem cell factor.
[0019] Preferably, the megakaryocyte differentiation medium further comprises a ROCK inhibitor.
[0020] More preferably, the above ROCK inhibitor is Y-27632.
[0021] More preferably, the megakaryocyte differentiation medium comprises 10 μM Y-27632.
[0022] In a preferred embodiment, the platelet maturation medium comprises ITS, glutamine (Glutamax), monothioglycerol (monothioglycerol), ascorbic acid (ascorbic acid), FBS, penicillin-streptomycin (PS), heparin (Heparin), human thrombopoietin (hTPO), ROCK inhibitor, ADAM17 inhibitor, and AhR antagonist.
[0023] Preferably, the platelet maturation medium comprises IMDM medium (Iscove modified Dulbecco Medium, IMDM), 1× insulin-transferrin-selenium, 1× glutamine, 0.45 mM thioglycerol, 50 μg / mL ascorbic acid, 15% FBS, 1× penicillin-streptomycin, 10 U / mL heparin, 50 ng / mL human thrombopoietin, 10 μM Y-27632, 15 μM KP-457 and 0.75 μM SR-1.
[0024] The present invention also provides a differentiation medium, which comprises SFEM medium, 50-100 ng / mL human thrombopoietin, and 50 ng / mL stem cell factor.
[0025] Preferably, the differentiation medium comprises SFEM medium, 100 ng / mL human thrombopoietin, and 50 ng / mL stem cell factor.
[0026] More preferably, the above differentiation medium further comprises a ROCK inhibitor.
[0027] More preferably, the above ROCK inhibitor is Y-27632.
[0028] On the other hand, the present invention provides a maturation medium, which comprises insulin-transferrin-selenium, glutamine, thioglycerol, ascorbic acid, FBS, penicillin-streptomycin, heparin, human thrombopoietin, ROCK inhibitor, ADAM17 inhibitor, and AhR antagonist.
[0029] Preferably, the above-mentioned maturation culture medium contains IMDM culture medium, 1× insulin-transferrin-selenium, 1× glutamine, 0.45mM thioglycerol, 50μg / mL ascorbic acid, 15% FBS, 1× penicillin-streptomycin, 10U / mL heparin, 50ng / mL human thrombopoietin, 10μM Y-27632, 15μM KP-457, and 0.75μM SR-1.
[0030] The present invention provides the steps of large-scale preparation of platelets:
[0031] First, add the incubated human umbilical cord blood stem cells into a polystyrene tube, place the tube on a magnetic pole for separation, remove the supernatant, and repeat this step three times to obtain a high-purity hematopoietic stem cell specific subset (CD34 + ).
[0032] Next, high-purity CD34 + Hematopoietic stem cells were cultured in vitro to obtain a large number of high-purity CD34 + Hematopoietic stem cells are helpful for obtaining a large number of megakaryocytes.
[0033] The CD34 + Hematopoietic stem cells are seeded in megakaryocyte differentiation medium. In some embodiments, the megakaryocyte differentiation medium is SFEM medium with 50-100 ng / mL human thrombopoietin and 50 ng / mL stem cell factor added; 10 μM Y-27632 can also be added to reduce cell apoptosis. The highest yield of megakaryocytes can be obtained by culturing with the megakaryocyte differentiation medium for 11 days.
[0034] Thereafter, the culture medium of megakaryocytes is replaced with platelet maturation medium to promote the maturation of platelets. In some embodiments, an optimized maturation medium is used, which contains 1×ITS, 1×glutamine, 0.45mM thioglycerol, 50μg / mL ascorbic acid, 15% high-filtered FBS, 1×penicillin-streptomycin, 10U / mL heparin, 50ng / mL human thrombopoietin, 10μM Y-27632, 15μM KP-457, and 0.75μM SR-1 added to IMDM culture medium.
[0035] During the platelet culture process, the culture medium can be horizontally shaken at a speed of 90 rpm and placed in an environment of 37 degrees Celsius and 5% CO2; or the cells can be stirred and cultured at a speed of 100 rpm and placed in an environment of 37 degrees Celsius and 5% CO2. After culturing the platelets for 6-12 days, the mature platelets are collected by centrifugation and tested.
[0036] Compared with the prior art, the present invention has the following beneficial effects:
[0037] 1. Isolation of CD34 stem cell subsets from blood samples + , making the starting cells purer, so as to better achieve downstream differentiation, such as megakaryocyte differentiation.
[0038] 2. The optimized megakaryocyte differentiation medium can ensure the production of higher quality and purity megakaryocytes, which is beneficial to the yield and purity of platelets.
[0039] 3. Optimized platelet maturation medium to improve platelet differentiation efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations of the present invention. In the drawings:
[0041] Figure 1 It refers to the process of preparing platelets in vitro. CD34 + HPCs are used as starting cells, and then HPCs are induced to differentiate into megakaryocytes. Under the action of optimized maturation culture medium, megakaryocytes are further matured to produce platelets.
[0042] Figure 2 It indicates the result of the in vitro aggregation function test of differentiated platelets. In vitro differentiated platelets can form an interwoven network structure in the presence of CaCl2, ADP and fibrinogen, and the interwoven effect becomes more complete as the concentration of CaCl2 increases. DETAILED DESCRIPTION
[0043] The present invention is further described below in conjunction with the accompanying drawings and specific examples, and the protection content of the present invention is not limited to the following examples. It should also be understood that the terms used in the examples of the present invention are to describe specific specific embodiments, rather than to limit the scope of protection of the present invention. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are all included in the present invention, and the attached claims and any equivalents thereof are the scope of protection of the present invention.
[0044] All technical and scientific terms used herein have the same meanings as generally understood by those skilled in the art to which the present invention belongs. In other cases, certain terms used herein will be explained in the specification. The experimental methods in the following examples without specifying specific conditions are common knowledge and common common sense of those skilled in the art. The features in the embodiments and embodiments of the present application can be combined with each other.
[0045] In the specification and claims of the present invention, unless otherwise expressly stated, the singular forms "a", "an" and "the" include plural forms. The experimental methods in the following examples without specifying specific conditions are all common knowledge and common common sense of those skilled in the art, or are in accordance with the conditions recommended by the manufacturer. Unless otherwise specified, all materials and reagents used in the examples are commercially available products.
[0046] The features and advantages of the present invention can be further understood through the following detailed description in conjunction with the accompanying drawings. The embodiments provided are only illustrative of the method of the present invention and do not limit the rest of the content disclosed by the present invention in any way.
[0047] The present invention aims to provide a method for large-scale preparation of platelets, wherein CD34 + Hematopoietic stem cells are used to expand the number of starting cells through the proliferation of hematopoietic stem cells. Then, an optimized megakaryocyte differentiation and platelet maturation culture medium, as well as the physical conditions for platelet production, are used to establish an in vitro method for preparing platelets with high purity, high yield and high differentiation efficiency.
[0048] Example 1: Specific subpopulations of human umbilical cord blood hematopoietic stem cells (CD34 + HPC) separation and purification
[0049] 1) Collect umbilical cord blood in an anticoagulant tube and mix well, and store or transport it at room temperature for a short time;
[0050] 2) Collect umbilical cord blood in a 50 mL centrifuge tube under sterile conditions, with a maximum collection volume of 17 mL;
[0051] 3) Add RosetteSep Cocktail (STEMCELL, #17897) to the cord blood at a ratio of 5 μL / mL, mix well and incubate at room temperature for 10 minutes;
[0052] 4) Add an equal volume of dilution buffer (SB Buffer: PBS with 2% FBS and 1 mM EDTA) and mix well;
[0053] 5) In 50mL SepMate TM -50 (STEMCELL, 386450-1) was added with 15 mL of density gradient centrifugation solution Lymphoprep (STEMCELL, #07801), and then the cord blood diluted in the previous step was poured in;
[0054] 6) Centrifuge at 1200g for 10 minutes. After separation, quickly pour the upper layer into a new 50mL centrifuge tube;
[0055] 7) Fill the centrifuge tube with SB buffer;
[0056] 8) Centrifuge at 300g for 10 minutes, carefully remove the supernatant, and add 0.5mL SB buffer to suspend the cells;
[0057] 9) Add the cells to a 12×75 mm 5 mL round-bottom polystyrene tube;
[0058] 10) Add Selection Cocktail (STEMCELL, #17897) at a ratio of 100 μL / mL, mix well and incubate at room temperature for 10 minutes;
[0059] 11) Add RapidSpheres (STEMCELL, #17897) at a ratio of 50 μL / mL, mix well and incubate at room temperature for 1 minute;
[0060] 12) Add appropriate amount of SB buffer to make the final volume 2.5 mL;
[0061] 13) Place the polystyrene tube in a magnetic pole (STEMCELL, #18000) and leave at room temperature for 3 minutes to separate the cells. Then remove the supernatant and add an appropriate amount of SB buffer again to make the final volume 2.5 mL;
[0062] 14) Repeat step 13) three more times;
[0063] 15) Transfer the cells to a new 15 mL centrifuge tube, centrifuge at 300 g for 10 minutes, slow down, and remove the supernatant;
[0064] 16) Resuspend the cells in 250 μL SEFM medium (STEMCELL, #09650) and count.
[0065] Example 2: CD34 + In vitro culture and expansion of HPC
[0066] 1) Add 2×10 4 The cells were seeded in a low-adsorption 6-well plate at a ratio of 1:1 cells / well and cultured at 37 degrees Celsius with 5% CO2. The medium was changed every 2-3 days, with 3 / 4 of the fresh expansion medium replaced each time.
[0067] 2) Expansion medium: Add 1 / 10 volume of StemSpan to SFEM medium TM Amplification Supplement (STEMCELL, #02691);
[0068] 3) The cells were cultured in the expansion medium and passaged approximately every 3 days, each time by centrifugation (1000 rpm, 5 minutes, room temperature) at a ratio of 1:5. The total expansion time should not exceed 12 days from the start of using the expansion medium;
[0069] 4) Count the cells every two days to record the cell doubling curve;
[0070] 5) The cells were stained with CD34 (BD Biosciences, 340669) and / or CD45 (BD Pharmingen, 555482) and CD34 expression was determined by flow cytometry or immunofluorescence assay. + The proportion of HPC.
[0071] Example 3: Preparation of platelets from human umbilical cord blood
[0072] 3.1 Differentiation of Megakaryocytes:
[0073] Add 5 × 10 5 The proportion of CD34 + HPCs were seeded in low-adsorption 6-well plates and cultured at 37 degrees Celsius and 5% CO2. The medium was changed every 2-3 days, with 3 / 4 of the differentiation medium replaced each time.
[0074] Differentiation medium: SFEM medium was supplemented with 50 ng / mL human thrombopoietin (hTPO; Peprotech, 300-18) and 50 ng / mL stem cell factor (SCF; Peprotech, 300-07).
[0075] Optimization method 1: Increasing the content of human thrombopoietin in the differentiation medium to 100 ng / mL can improve the efficiency of megakaryocyte differentiation.
[0076] Optimization method 2: Adding 10 μM Y-27632 (Selleck, S1049) to the differentiation medium can reduce the number of apoptotic cells.
[0077] 3.2 Detection of megakaryocytes:
[0078] The maximum yield of megakaryocytes can be achieved after about 11 days of differentiation, starting from the use of differentiation medium. The purity of megakaryocytes can be determined by staining the cells for CD41a (BD Pharmingen, 555467) and CD42b (BD Pharmingen, 555472) and then performing flow cytometry analysis or immunofluorescence experiments.
[0079] 3.3 Platelet maturation:
[0080] The culture medium of megakaryocytes is replaced with a maturation medium to promote the maturation of platelets. Platelets are generally collected and functionally tested 6-12 days after the maturation medium is replaced.
[0081] Maturation medium: Iscove modified Dulbecco Medium (IMDM; Thermofisher, 12440053) was supplemented with 1× insulin-transferrin-selenium (ITS) (Thermofisher, 41400045), 1× glutamine (Glutamax; thermofisher, 35050-061), 0.45 mM monothioglycerol (Sigma, M6145), 50 μg / mL ascorbic acid (Sigma, A4544), 15% highly filtered Filtered) FBS (Gibico, 10100147), 1× Penicillin-Streptomycin (thermofisher, 15140122), 10U / mL Heparin (Heparin; STEMCELL, #07980), 50ng / mL human thrombopoietin (hTPO), 10μM Y-27632, 15μM KP-457 (MCE, HY-110397), 0.75μM SR-1 (Merck Millipore, 182706).
[0082] Optimization method 1: After replacing the maturation culture medium, the cells were placed on a horizontal shaker for shaking culture at a speed of 90 rpm, 37 degrees Celsius, and 5% CO2; the maturation efficiency of this method is higher than that of static culture.
[0083] Optimization method 2: After replacing the maturation culture medium, place the cells in a 50mL centrifuge tube, with a total culture system of 20mL, add a stirring paddle (cross-shaped, 4 leaves, leaf width 0.8cm) to stir the cells for culture, stirring speed 100rpm, 37 degrees Celsius, 5% CO2; this method has the highest platelet maturation efficiency.
[0084] Example 4: In vitro platelet aggregation function test
[0085] Mature platelets were collected by two-step centrifugation (800 rpm, 5 minutes to collect the supernatant, and the supernatant was centrifuged again at 2500 rpm for 10 minutes to collect the precipitate). After counting the platelets, in vitro aggregation function test was performed: 1-100×10 5Platelets, 1-10 mM CaCl2, 10 μM ADP (Sigma, A2754-500MG) and 10 μg / mL fibrinogen (Fibrinogen; Sigma, F3879-100MG), PBS was added to make up to 100 μL. After pipetting and mixing, the cells were placed in a 37°C incubator for reaction. Microscopic photographs of the cells were taken at 0 and 24 hours of reaction (see the results). Figure 2 ), the results showed that in the presence of CaCl2, ADP and fibrinogen, an interwoven network structure can be formed, and as the concentration of CaCl2 increases, the interweaving effect becomes more complete.
[0086] All documents mentioned in the present invention are cited in their entirety in this application as reference. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these modifications in equivalent forms also fall within the scope defined by the claims of the present application.
Claims
1. A method for preparing platelets in vitro, characterized in that: The following steps are involved: 1) Isolate and purify stem cells from blood samples; 2) Culture in megakaryocyte differentiation medium, add 5×10 5 The stem cells are seeded in a low-adsorption 6-well plate at a ratio of 100 cells / mL, cultured at 37 degrees Celsius and 5% CO2, and the medium is changed every 2-3 days, with 3 / 4 of the fresh differentiation medium replaced each time; wherein the megakaryocyte differentiation medium comprises SFEM medium, 100 ng / mL human thrombopoietin, and 50 ng / mL stem cell factor; 3) After replacing the platelet maturation medium, the cells were placed in a 50 mL centrifuge tube with a total culture system of 20 mL, and a stirring paddle was added to stir the cells at a stirring speed of 100 rpm, 37 degrees Celsius, and 5% CO2, wherein the stirring paddle was a cross-shaped stirring paddle with 4 blades and a blade width of 0.8 cm; or: replaced with platelet maturation medium, the cells were placed on a horizontal shaker for shaking culture at a speed of 90 rpm, 37 degrees Celsius, and 5% CO2; wherein the platelet maturation medium comprises IMDM medium, 1× insulin-transferrin-selenium, 1× glutamine, 0.45 mM thioglycerol, 50 µg / mL ascorbic acid, 15% FBS, 1× penicillin-streptomycin, 10 U / mL heparin, 50 ng / mL human thrombopoietin, 10 µM Y-27632, 15 µM KP-457, and 0.75 µM SR-1; 4) Collect mature platelets 6-12 days after replacing the platelet maturation medium.
2. The method according to claim 1, characterized in that The blood sample is human umbilical cord blood.
3. The method according to claim 1, characterized in that The separation and purification step is to separate the stem cells in the blood sample through magnetic force.
4. The method according to claim 1, characterized in that: The stem cells are CD34 + Human hematopoietic stem cells.
